Shelley Force Aldred, PhD, brought updates on some of the latest research in therapeutic antibody development to the HudsonAlpha Institute for Biotechnology in her talk for this week’s seminar. Aldred comes to the institute from TeneoBio, where she is the Vice President for Preclinical Development.
Aldred outlined the process by which researchers identify promising antibodies that could be harnessed for medical treatments. Advances in sequencing technology have opened up a whole new host of approaches. For example, next-generation sequencing allows researchers to profile an immune system’s antibody repertoire. This empowers researchers to more effectively identify and test potential treatments.
This seminar was hosted by Rick Myers, PhD.
More information on HudsonAlpha Research Seminars, including the upcoming schedule, can be found at hudsonalpha.org/seminars.